Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus, Inc. (Nasdaq: SLP) reported a 17% total revenue growth for Q3 fiscal 2022, reaching $15.0 million. The software revenue rose by 16% to $9.7 million, while services revenue grew by 19% to $5.3 million. Diluted EPS increased by 11% to $0.20, with a net income of $4.1 million. The company reiterated its full-year revenue guidance of $52-53 million and announced a quarterly dividend of $0.06 per share, payable August 1, 2022.
Simulations Plus, Inc. (Nasdaq: SLP) reported record attendance at the 2022 Pharmacometrics Spring School, with 936 participants from over 50 countries. The event featured workshops on model-informed drug development and clinical trial simulations using the MonolixSuite and PKanalix platforms, both offered free to attendees. Dr. Jonathan Chauvin highlighted strong community interest which supports the company's position as a leader in modeling and simulation software. The company aims to continue these workshops in 2023.
Simulations Plus, Inc. (NASDAQ: SLP) revealed its Cognigen division's collaboration with a major pharmaceutical firm to enhance the development of a COVID-19 therapy. This partnership facilitated modeling and simulation activities, significantly contributing to regulatory submissions. The project focused on real-time data processing, improving insights on pharmacokinetics and efficacy throughout clinical trials. Cognigen division president Jill Fiedler-Kelly emphasized the essential role of these services in optimizing drug development efficiency.
Simulations Plus (SLP) will report its third-quarter financial results for fiscal year 2022, ending May 31, 2022, after market close on July 6, 2022. A conference call will be held at 5:00 PM ET on the same day, allowing stakeholders to engage with company representatives. Interested parties can join the call by registering here or by calling 1-201-389-0879.
Simulations Plus (NASDAQ: SLP) has published simulation results utilizing its DILIsym software, featured in Toxicological Sciences. These results illustrate the liver safety differences between small molecule CGRP receptor antagonists, addressing past failures in this drug class like telcagepant. DILIsym has effectively predicted the safety of newer candidates, contributing to the FDA approval of rimegepant in 2021. This research, co-authored by Jeffrey Woodhead, reinforces DILIsym's role in guiding drug development with an emphasis on safety.
Simulations Plus (NASDAQ: SLP) has released version 10.4 of its flagship ADMET Predictor machine learning platform, enhancing capabilities for pharmaceutical modeling. Key features include new 3D conformer generation, expanded mouse models for the HTPK Simulation Module, and improved Ames mutagenicity models for reliability. The enhancements are aimed at improving drug discovery processes. The company is focused on advancing artificial intelligence in drug design and has noted increased adoption of its technologies in recent years.
Simulations Plus has announced the renewal of its DILIsym software licenses by the FDA, ensuring uninterrupted access for FDA employees across all divisions. This one-year renewal reflects the FDA's continued reliance on DILIsym for evaluating drug-induced liver injury (DILI) risks, which is critical for drug development decisions. The software aids in predicting DILI risks and identifying patient subgroups vulnerable to such injuries, thereby mitigating financial losses from failed clinical trials.
Simulations Plus, Inc. (NASDAQ: SLP) announced the completion of a project funded by the U.S. FDA and the Center for Research on Complex Generics. The collaboration, involving the Lixoft and Cognigen divisions, aims to demonstrate bioequivalence for long-acting injectables (LAI) using a novel model-integrated design. This method could alleviate the challenges of low power and prolonged duration in bioequivalence trials. The results were presented at an FDA workshop on Nov. 30, 2021.
Simulations Plus (Nasdaq: SLP) has announced a funded partnership with a major pharmaceutical company to enhance mechanistic dissolution models for injectable formulations using their DDDPlus™ software. This collaboration aims to improve in vitro analysis of drug product specifications and capture dissolution kinetics more effectively. Senior scientists expressed enthusiasm about expanding market opportunities in injectables, while the company retains ownership of all software improvements. Simulations Plus continues to support global pharmaceutical development through innovative biosimulation solutions.
Simulations Plus, a leader in modeling and simulation software for pharmaceutical safety, announced participation in the Berenberg Discover AI Seminar on April 26, 2022, in Boston, Massachusetts. CEO Shawn O’Connor will hold one-on-one meetings during the event. For details on the seminar, the slide presentation will be accessible on the Simulations Plus Investors page. With 25 years of experience, Simulations Plus supports drug discovery and regulatory submissions through advanced software solutions licensed by major pharmaceutical companies and regulatory agencies worldwide.